← Back to news
🔴 BreakingNewsFDAFriday, May 8, 2026 · May 8, 2026

FDA Grants Seventh Approval under the National Priority Voucher Pilot Program

WHY IT MATTERS

FDA announcement relevant to rare disease patients and caregivers.

FDA issued an approval for Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma, an ultra-rare, aggressive cancer that forms in the bile ducts.

View FDA Announcement
Read the original at FDA
FDA ApprovalTreatment

Related news

FDA
FDA Approves XTORO
XTORO (FINAFLOXACIN) received FDA approval.
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.
FDA
FDA Approves SABRIL
SABRIL (VIGABATRIN) received FDA approval.
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.